{"url_path":"/sec/slxn/8-k/2026-07-21/item-5-03","section_key":"item-5-03","section_title":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","accession_number":"0001178913-26-003551","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":141,"has_tables":true,"body_markdown":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.\n\nAt the extraordinary general meeting of Silexion Therapeutics Corp (the “Company”) originally held on July 13, 2026 and reconvened on July 20, 2026 (the “Meeting”),\n\nthe shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “Memorandum Amendment”), which increased the Company’s authorized share capital, as described in Item 5.07 below. The Memorandum Amendment was filed with the Registrar of Companies of the Cayman Islands on July 21,\n2026, at which time it became effective.\n\nThe above description of the Memorandum Amendment is a summary of the material terms thereof and is qualified in its\nentirety by reference to the Memorandum Amendment, a copy of which is attached as [Exhibit 3.1](exhibit_3-1.htm) hereto."}